A detailed history of Alliancebernstein L.P. transactions in Precigen, Inc. stock. As of the latest transaction made, Alliancebernstein L.P. holds 226,660 shares of PGEN stock, worth $206,260. This represents 0.0% of its overall portfolio holdings.

Number of Shares
226,660
Previous 226,660 -0.0%
Holding current value
$206,260
Previous $358,000 39.94%
% of portfolio
0.0%
Previous 0.0%

Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.27 - $1.75 $53,200 - $73,307
41,890 Added 22.67%
226,660 $358,000
Q4 2023

Feb 14, 2024

SELL
$0.89 - $1.41 $10,662 - $16,891
-11,980 Reduced 6.09%
184,770 $247,000
Q3 2023

Nov 14, 2023

SELL
$1.08 - $1.85 $12,798 - $21,922
-11,850 Reduced 5.68%
196,750 $279,000
Q2 2023

Aug 15, 2023

BUY
$0.96 - $1.4 $43,296 - $63,139
45,100 Added 27.58%
208,600 $239,000
Q1 2023

May 15, 2023

SELL
$0.88 - $2.19 $1,760 - $4,380
-2,000 Reduced 1.21%
163,500 $173,000
Q4 2022

Feb 14, 2023

BUY
$1.27 - $2.26 $7,620 - $13,559
6,000 Added 3.76%
165,500 $251,000
Q3 2022

Nov 15, 2022

BUY
$1.41 - $2.79 $35,955 - $71,145
25,500 Added 19.03%
159,500 $338,000
Q2 2022

Aug 15, 2022

BUY
$1.15 - $2.53 $16,329 - $35,926
14,200 Added 11.85%
134,000 $180,000
Q1 2022

May 13, 2022

BUY
$1.91 - $3.98 $573 - $1,194
300 Added 0.25%
119,800 $253,000
Q2 2021

Jul 30, 2021

BUY
$6.24 - $8.22 $244,608 - $322,224
39,200 Added 48.82%
119,500 $779,000
Q1 2021

May 06, 2021

SELL
$6.74 - $10.95 $89,642 - $145,635
-13,300 Reduced 14.21%
80,300 $553,000
Q4 2020

Feb 08, 2021

SELL
$3.75 - $10.56 $87,750 - $247,104
-23,400 Reduced 20.0%
93,600 $955,000
Q3 2020

Nov 12, 2020

SELL
$3.5 - $6.2 $75,950 - $134,540
-21,700 Reduced 15.65%
117,000 $410,000
Q2 2020

Aug 13, 2020

BUY
$2.16 - $5.46 $58,536 - $147,966
27,100 Added 24.28%
138,700 $692,000
Q1 2020

May 14, 2020

BUY
$1.46 - $7.19 $162,936 - $802,404
111,600 New
111,600 $379,000

Others Institutions Holding PGEN

About PRECIGEN, INC.


  • Ticker PGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 208,150,000
  • Market Cap $189M
  • Description
  • Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...
More about PGEN
Track This Portfolio

Track Alliancebernstein L.P. Portfolio

Follow Alliancebernstein L.P. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alliancebernstein L.P., based on Form 13F filings with the SEC.

News

Stay updated on Alliancebernstein L.P. with notifications on news.